Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health - Takeaways - MDSpire

Novel myo-inositol to butyrate fermentation pathway in the prevalent human gut species Dysosmobacter welbionis, a bacterium associated with improved metabolic and liver health

  • By

  • Chi-Hsien Lee

  • Thi Phuong Nam Bui

  • Camille Petitfils

  • Ching Jian

  • Giselle C Wong

  • Anthony Puel

  • Tiphaine Le Roy

  • Samuel Bellais

  • Bouthaina Ben Abdallah

  • Mélanie Nehlich

  • Thomas Leicht

  • Manyi Jia

  • Lesley Hoyles

  • Massimo Federici

  • Jose Manuel Fernández-Real

  • Remy Burcelin

  • Marc-Emmanuel Dumas

  • Nathalie M Delzenne

  • Thomas Clavel

  • Sjef Boeren

  • Antonio Dario Troise

  • Andrea Scaloni

  • Giulio G Muccioli

  • Willem M De Vos

  • Matthias Van Hul

  • Patrice D Cani

  • July 1, 2026

  • 0 min

Share

  • 1

    Dysosmobacter welbionis converts myo-inositol to butyrate, a previously uncharacterized metabolic pathway in gut bacteria.

  • 2

    The abundance of D. welbionis is reduced in metabolic-associated fatty liver disease, indicating a potential protective role in liver health.

  • 3

    This study shows that the inositol-to-butyrate pathway is conserved across multiple strains of D. welbionis, reinforcing its ecological relevance.

  • 4

    Advanced techniques were employed to isolate D. welbionis strains and map the unique biochemical steps of the fermentation pathway.

  • 5

    D. welbionis may serve as a next-generation probiotic for managing metabolic diseases like obesity and type 2 diabetes.

Original Source(s)

Related Content